SureTrader Stock Hero Advertisement SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Titan Pharmaceuticals (TTNP)

TTNP RSS Feed
Add TTNP Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator interstate, TRUTH, matthewverymuch, Ppower
Search This Board:
Last Post: 4/21/2015 5:18:31 AM - Followers: 168 - Board type: Free - Posts Today: 2


 






Products


Probuphine®-This study is enrolling participants by invitation only.

Click For Link To ClinicalTrials.gov


*November 20, 2014 -  the study is 100% enrolled. 
   * First patients enrolled on Jul 21, 2014 *                                  * DrKate Glassman-Beebe- Executive Vice President and Chief Development Officer-Titan Pharmaceuticals

Click For cnn.com Link 


Sponsor:

Braeburn Pharmaceuticals


ClinicalTrials.gov Identifier:
Information provided by (Responsible Party):
NCT02180659
First received: July 1, 2014
Last updated: July 8, 2014
Last verified: July 2014
Braeburn Pharmaceuticals









Probuphine Graphic

 

 

 

Continuous Drug Delivery Technology

 

The continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (“EVA”) and a drug substance. The resulting product is a solid matrix that is placed subcutaneously, normally in the inner part of the upper arm in a simple office procedure, and is removed in a similar manner at the end of the treatment period. The drug substance is released slowly, at continuous levels, through the process of dissolution. This results in a stable blood level similar to intravenous administration. Such long-term, linear release characteristics are generally desirable as this avoids peak and trough level dosing that poses problems for many Central Nervous System (“CNS”) and other disease settings.

This continuous drug delivery technology was developed to address the need for a simple, practical method to potentially provide continuous drug administration on an outpatient basis over extended periods of up to 6-12 months. In addition to Probuphine, which is the first product to complete clinical testing that has utilized this proprietary continuous drug delivery technology, Titan has conducted initial non-clinical studies with long-term delivery of dopamine agonists demonstrating the potential of this product in the treatment of Parkinson’s disease in non-clinical models of the disease.

 



Fanapt® (iloperidone)

 

Fanapt (iloperidone) is an atypical antipsychotic approved by the FDA for the treatment of schizophrenia currently being marketed by Novartis Pharma AG (“Novartis”) in the U.S. Titan is entitled to a royalty of 8-10% of net sales of Fanapt under a sublicense agreement with Novartis that is based on a U.S. patent which expires in October 2016 (does not include a possible six-month pediatric extension).

Titan has entered into several agreements with Deerfield Management LP (“Deerfield”), which entitle Deerfield to most of the future royalty revenues related to Fanapt in exchange for cash and debt considerations, the proceeds of which have been used to advance the development of Probuphine and for general corporate purposes. Titan has retained a portion of the royalty revenue from net sales of Fanapt in excess of specified annual threshold levels; however, based on sales levels to date, it is unlikely that Titan will retain any revenue from Fanapt in the next several years, if ever. Titan does not incur any ongoing expenses associated with this product.




Company Overview



Titan Pharmaceuticals, Inc is a biopharmaceutical company focused in the development of products for the treatment of central nervous system (CNS) diseases. Titan's first out licensed product, Fanapt® (iloperidone) is an atypical antipsychotic approved in the U.S. in May 2009 for the treatment of schizophrenia in adult patients. It is currently marketed in the U.S. by Novartis Pharma, AG, and Titan is entitled to receive 8-10% of global annual sales as royalty revenue for the term of the licensed patents.

 

Titan's second product, Probuphine, is nearing completion of the Phase 3 clinical development program in the treatment of opioid addiction. Probuphine is a novel, subcutaneous implant formulation of buprenorphine designed to deliver six months of medication following single treatment. This product has already demonstrated strong positive results in the first controlled Phase 3 study for the treatment of opioid addiction. The confirmatory Phase 3 study is currently being conducted at 20 sites in the U.S., and the results of this study are expected in Q2, 2011. Additional information on the Probuphine program is available in the PRODUCTS section of this website.


 

The Company's common stock is traded on the OTC Bulletin Board Markets ([TTNP.OB] www.otcbb.com) quotations system. For further information please contact info@titanpharm.com

 

Management Team

President
Sunil Bhonsle, M.B.A.

Executive Vice President and Chief Development Officer

Katherine L. Beebe, Ph.D.

Executive Chairman

Marc Rubin, M.D.

 



Board of Directors

 
 
  






 

Strategic Alliances


In December 2012, Titan entered into a license agreement with Braeburn Pharmaceuticals Sprl (“Braeburn”) that grants Braeburn exclusive commercialization rights to Probuphine® in the United States and Canada. Titan received a non-refundable up-front license fee of $15.75 million and will receive a $50 million milestone payment upon the approval of the NDA by the FDA. Additionally, Titan will be eligible to receive up to $130 million upon achievement of specified sales milestones and up to $35 million in regulatory milestones in the event of future NDA submissions and approvals for additional indications, including chronic pain. Titan will receive tiered royalties on net sales of Probuphine ranging from the mid-teens to the low twenties.

 





Product Overview

The investigational products are at various stages of development as listed below.

Titan Pharmaceuticals Products

In addition to the potential royalty revenues from iloperidone, Titan is currently focused on adding value to the company from these assets, particularly Probuphine. Additional information on Probuphine and other programs are available in the next sections. If you are interested in learning more, please contact Sunil Bhonsle, President, at     sbhonsle@titanpharm.com

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TTNP
Current Price
Volume:
Bid Ask Day's Range
Wiki
TTNP News: TITAN PHARMACEUTICALS (TTNP) SHAREHOLDER ALERT – Andrews & Springer LLC Is Investigating Titan Pharmaceuticals, Inc. For Po... 04/08/2015 08:13:00 AM
TTNP News: Annual Report (10-k) 03/31/2015 12:42:08 PM
TTNP News: Statement of Changes in Beneficial Ownership (4) 03/18/2015 07:48:51 PM
TTNP News: Statement of Changes in Beneficial Ownership (4) 03/18/2015 07:45:45 PM
TTNP News: Statement of Changes in Beneficial Ownership (4) 03/18/2015 07:44:09 PM
PostSubject
#3684  Sticky Note ****Addicts DESPERATELY Waiting For A Lifesaver**** TRUTH 09/27/14 11:41:37 AM
#4794   What Dopamine Tells Us About Opioid Addiction TRUTH 04/21/15 05:18:31 AM
#4793   Senators Urge More Research Funding For Prescription Drug Abuse TRUTH 04/21/15 03:37:58 AM
#4792   Just caught the lasr few seconds on cable turks 04/20/15 11:15:02 PM
#4791   New Abuse-Deterrent Formulations Reduce Opiate Prescriptions And Overdoses[/b TRUTH 04/20/15 02:21:12 PM
#4790   Truth I'm glad you got my humor, FUN, turks 04/20/15 02:13:06 PM
#4789   you have been a godsend to the board... TRUTH 04/20/15 02:04:14 PM
#4788   TRUTH... you have been a godsend to the interstate 04/20/15 01:43:27 PM
#4787   Funny how time flies when having fun.......lol. TRUTH 04/20/15 12:17:24 PM
#4786   The Probuphine Team (sounds a lot better than TRUTH 04/20/15 12:00:04 PM
#4785   I would hardly say time has flown. Excruciatingly matthewverymuch 04/20/15 11:45:45 AM
#4784   Amazing one month left from today for trial turks 04/20/15 10:01:58 AM
#4783   Concerns Grow With Spike In Heroin Overdoses In TRUTH 04/20/15 07:13:05 AM
#4782   Program Would Help, Encourage Individuals To Live Free TRUTH 04/20/15 01:43:19 AM
#4781   ****THE HARD FACTS ABOUT PRESCRIPTION DRUG ADDICTION**** TRUTH 04/20/15 01:01:15 AM
#4780   Working Together TRUTH 04/20/15 12:55:57 AM
#4779   Hello turks, TRUTH 04/19/15 12:43:58 PM
#4778   A thought just hit me while posting my turks 04/19/15 12:18:52 PM
#4777   Hey truth, every time now that I read turks 04/19/15 11:45:01 AM
#4776   Prescription Painkiller And Heroin Abuse: Do You Have TRUTH 04/19/15 09:13:54 AM
#4775   No TRUTH I mean as long as they bluejacket6 04/19/15 01:46:35 AM
#4774   Hope they push our pps down another nickel TRUTH 04/19/15 01:06:26 AM
#4773   Hope they push our pps down another nickel bluejacket6 04/19/15 12:45:30 AM
#4772   Prescription Drug Overdose Deaths Rising Among Older Minnesotans TRUTH 04/18/15 04:03:37 PM
#4771   Opiate Epidemic Rages On In Middlesex County TRUTH 04/18/15 03:45:44 PM
#4770   Officials Fear Scourge Of Heroin Could Hit Tri-State TRUTH 04/18/15 01:14:55 PM
#4769   Council Reverses Vote, Gets OD Antidote TRUTH 04/17/15 11:46:39 PM
#4768   You are doing a great job in educating turks 04/17/15 05:56:11 PM
#4767   I post these article simply to educate any TRUTH 04/17/15 02:18:36 PM
#4766   The way i understand it, the fda wanted matthewverymuch 04/17/15 02:01:57 PM
#4765   Why would the results not be deemed successful. interstate 04/17/15 01:50:09 PM
#4764   Proove Bisociences To Participate In The Buzz of TRUTH 04/17/15 12:03:06 PM
#4763   Pittsburgh's Federal Prosecutor Picked To Co-Chair National Heroin TRUTH 04/17/15 11:50:58 AM
#4762   Why Supposedly Abuse-Proof Pills Won't Stop Opioid Overdose Deaths TRUTH 04/17/15 11:34:00 AM
#4761   Truth, I just want to say I, me, turks 04/17/15 07:59:12 AM
#4760   If we could only turn back the clock.... TRUTH 04/16/15 11:33:30 PM
#4759   Truth,now if this llegislation was around April 31 turks 04/16/15 08:41:12 PM
#4758   holding above .7 is a great sign for me. TRUTH 04/16/15 06:25:57 PM
#4757   38.52% TTNP Volume Shorted Today TRUTH 04/16/15 05:42:52 PM
#4756   Capito Statement On Legislation To Hold FDA Accountable TRUTH 04/16/15 04:58:59 PM
#4755   Tougher FDA Approval Process For Opioids Sought By Congress TRUTH 04/16/15 04:49:39 PM
#4754   Historical Short Selling Data For TTNP TRUTH 04/16/15 04:37:42 PM
#4753   ridiculous amount of selling. TRUTH 04/16/15 03:59:07 PM
#4752   Do not worry about the %... worry about interstate 04/16/15 02:54:09 PM
#4751   Considering less than 10,000 shares bought at the matthewverymuch 04/16/15 02:09:22 PM
#4750   I would not say ridiculous amount of selling interstate 04/16/15 01:17:05 PM
#4749   Ameritox Delivers Testimony Before Maryland Heroin and Opioid TRUTH 04/16/15 12:37:16 PM
#4748   Ridiculous amount of selling going on today. What matthewverymuch 04/16/15 12:31:20 PM
#4747   Addressing Heroin Crisis From Addiction Treatment, Legislative Perspectives TRUTH 04/16/15 06:56:03 AM
#4746   Methadone And Buprenorphine 101: A Guide For Law Enforcement TRUTH 04/15/15 04:09:15 PM
#4745   I would settle with just having good data matthewverymuch 04/15/15 03:05:35 PM
PostSubject